Primary Central Nervous System Lymphoma clinical trials
17 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
- A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
- Pembrolizumab, Ibrutinib and Rituximab in PCNSL
- Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
- Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
- Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
- Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
- Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
- Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
- DALY II USA/ MB-CART2019.1 for DLBCL
- Q702 for the Treatment of Patients With Hematologic Malignancies
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Primary Central Nervous System Lymphoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.